# Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



سلطنة عُمان وزارة الصحة المديرية العامة للصيدلة والرقابة الدوائية مسقط

To:

# THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

**Director General of Royal Hospital** 

**Director General of Khoula Hospital** 

**Director General of Medical Supplies (MOH)** 

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 223 dated 23/10/2023 Regarding NCMDR FSCA of Human Assayed Multi-Sera Control Level 3 from (mfr: Randox Laboratories Ltd.).

### Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





# Sultanate of Oman Ministry of Health Directorate General of Pharmaceutical Affairs and Drug Control Muscat



سلطنة عُمان وزارة الصحة المديرية العامة للصيدلة والرقابة الدوائية مسقط

Circular No. 223/2023 Description of the Circular No. 223/2023 Overlag Forward with Confidence

وية <mark>عـُـمـان</mark> 2040 م

**S** -04-1445 H

23-10-2023

## Field Safety Corrective Action of Human Assayed Multi-Sera Control Level 3 from Randox Laboratories Ltd.

Source	NCMDR- National Center for Medical Devices Reporting- SFDA
	https://ncmdr.sfda.gov.sa/Secure/CA/CaViewRecall.aspx?caid=4&rid=19713
Product	Human Assayed Multi-Sera Control Level 3.
Description	IVD; In vitro diagnostic devices.
Manufacturer	Randox Laboratories Ltd.
Local Agent	Mustafa Sultan Science & Industry Co.LLC.
The affected products	Catalogue Number: HE1532
	GTIN: 05055273203608
	Batch / Lot number: 1294UE
	Expiry Date: 28 Oct 26
	Manufacturing Date: 16 May 23.
Reason	The stability for AST (GOT) has been reduced from 7 days to 6 days when stored at 2-8°C for the affected product listed above.
Action	<ol> <li>The Instructions For Use (IFU) have been updated and is now available on www.randox.com.</li> <li>Please discard any previous versions of the IFU and download the updated IFU.</li> <li>Contact the local agent for remedial action.</li> </ol>
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: <a href="Med-device@moh.gov.om">Med-device@moh.gov.om</a>

Dr. Mohammed Hamdan Al Rubaie

Director General



